BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11199936)

  • 1. Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.
    Hägg S; Mjörndal T; Lindqvist L
    J Clin Psychopharmacol; 2001 Feb; 21(1):113-5. PubMed ID: 11199936
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.
    Järventausta K; Leinonen E
    Acta Psychiatr Scand; 2000 Sep; 102(3):231-3. PubMed ID: 11008860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between olanzapine and haloperidol.
    Gomberg RF
    J Clin Psychopharmacol; 1999 Jun; 19(3):272-3. PubMed ID: 10350035
    [No Abstract]   [Full Text] [Related]  

  • 4. [Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].
    Joye F; Orrillard M; Marion F; Michoux I; Parisot R
    Ann Fr Anesth Reanim; 1999 Jun; 18(6):686-90. PubMed ID: 10464538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine and haloperidol: potential for neutropenia?
    Abdullah N; Voronovitch L; Taylor S; Lippmann S
    Psychosomatics; 2003; 44(1):83-4. PubMed ID: 12515844
    [No Abstract]   [Full Text] [Related]  

  • 6. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine and tardive dyskinesia.
    Woods SW
    Br J Psychiatry; 1999 Oct; 175():391-2. PubMed ID: 10789313
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Lu ML; Shen WW
    Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567
    [No Abstract]   [Full Text] [Related]  

  • 9. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
    Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
    J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety in treating bipolar disorder.
    Gupta S
    J Fam Pract; 2003 Mar; Suppl():S26-9. PubMed ID: 12676082
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
    Mujica R; Weiden P
    Am J Psychiatry; 2001 Apr; 158(4):650-1. PubMed ID: 11282706
    [No Abstract]   [Full Text] [Related]  

  • 12. Antipsychotic drugs and QT interval prolongation.
    Zareba W; Lin DA
    Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
    Robinson KA
    Clin Ther; 2000 Nov; 22(11):1375-6. PubMed ID: 11117662
    [No Abstract]   [Full Text] [Related]  

  • 14. Haloperidol-induced impotence improved by switching to olanzapine.
    Tsai SJ; Hong CJ
    Gen Hosp Psychiatry; 2000; 22(5):391-2. PubMed ID: 11203037
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic consequences of a drug-drug interaction.
    Shad MU; Marsh C; Preskorn SH
    J Clin Psychopharmacol; 2001 Feb; 21(1):119-20. PubMed ID: 11199940
    [No Abstract]   [Full Text] [Related]  

  • 17. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothermia in a hemodialysis patient treated with olanzapine monotherapy.
    Fukunishi I; Sato Y; Kino K; Shirai T; Kitaoka T
    J Clin Psychopharmacol; 2003 Jun; 23(3):314. PubMed ID: 12826994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.